T3 PHARMACEUTICALS
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.
T3 PHARMACEUTICALS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2015-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.t3pharma.com
Total Employee:
1+
Status:
Active
Contact:
+410612672074
Email Addresses:
[email protected]
Total Funding:
37 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving SSL By Default Google Maps LetsEncrypt Apple Mobile Web App Capable QUIC Google No Translate TYPO3
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Cellics Therapeutics
Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines.
GFBiochemicals
GFBiochemicals company to produce levulinic acid at commercial scale directly from biomass.
Mogrify
Mogrify® will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies.
Okomera
Okomera is a biotech start-up that accelerates access to improved, precision-based cancer therapies.
Polymateria
Polymateria is a startup advancing science to help nature deal with plastic pollution.
Proto Axiom
Proto Axiom on-shores pre-clinical R&D expertise to bridge the gap.
Qubit Pharmaceuticals
Qubit Pharmaceuticals is an EIT Health Headstart laureate and is incubated at Paris Biotech Santé.
Current Employees Featured
Founder
Investors List
Innosuisse
Innosuisse investment in Grant - T3 Pharmaceuticals
Swiss Economic Award
Swiss Economic Award investment in Grant - T3 Pharmaceuticals
Reference Capital SA
Reference Capital SA investment in Series C - T3 Pharmaceuticals
Wille Finance
Wille Finance investment in Series C - T3 Pharmaceuticals
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series C - T3 Pharmaceuticals
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - T3 Pharmaceuticals
Reference Capital SA
Reference Capital SA investment in Series B - T3 Pharmaceuticals
Swiss Federal Commission for Innovation and Technology
Swiss Federal Commission for Innovation and Technology investment in Series A - T3 Pharmaceuticals
Official Site Inspections
http://www.t3pharma.com Semrush global rank: 11.21 M Semrush visits lastest month: 222
- Host name: s007.cyon.net
- IP address: 149.126.4.16
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "T3 Pharmaceuticals"
home - T3 Pharma
Developing the next generation bacterial cancer therapy. Click here for more on T3 Pharma's technology...See details»
T3 Pharmaceuticals - Crunchbase Company Profile
Organization. T3 Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
T3 Pharma at a glance
The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for …See details»
T3 Pharmaceuticals AG – Swiss Biotech
Nov 22, 2023 The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments based on live bacteria. T3 Pharmaceuticals was acquired by Boehringer Ingelheim on 22 November 2023.See details»
T3 Pharmaceuticals AG - LinkedIn
Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments.See details»
Board of Directors - T3 Pharma
Lamine Mbow, PhD. Member of the Board of Directors. Lamine gained his PhD in immunology at the University of Neuchâtel, Switzerland, followed by postdoctoral training in host immunity at the CDC Fort Collins, CO and Colorado State …See details»
T3 Pharmaceuticals 2025 Company Profile: Valuation, Investors ...
T3 Pharmaceuticals General Information Description. Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary protein delivery …See details»
Boehringer acquires T3 Pharma | Boehringer Ingelheim
Nov 22, 2023 Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 PharmaSee details»
T3 Pharmaceuticals AG - startup.ch
T3 Pharmaceuticals AG: The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company …See details»
T3 Pharmaceuticals AG
Explore T3 Pharmaceuticals AG with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 7 news, and 2 literature, Disease Domain:Neoplasms ...See details»
T3 Pharma - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 23, 2025 T3 Pharma - Developer of novel and innovative medicines to treat cancer. Acquired by Boehringer Ingelheim. Raised a total funding of $42.7M over 3 rounds from 5 …See details»
T3 Pharmaceuticals - Overview, News & Competitors - ZoomInfo
T3 Pharmaceuticals contact info: Phone number: +41 612072074 Website: www.t3pharma.com What does T3 Pharmaceuticals do? T3 Pharmaceuticals is a pre-clinical biopharmaceutical …See details»
T3 Pharmaceuticals - Org Chart, Teams, Culture & Jobs - The Org
View T3 Pharmaceuticals' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
T3 Pharmaceuticals Company Information - Funding, Investors, …
Website: https://t3pharma.com; Business model: b2b Company size: 1 - 11 employees Headquarters: Basel, Switzerland Social accounts: Linkedin; Funding. Funding series. Funding …See details»
T3 Pharmaceuticals acquired by Boehringer Ingelheim - Crunchbase
Nov 22, 2023 Acquiring Organization: Boehringer Ingelheim Boehringer Ingelheim is a group of pharmaceutical companies that focuses on prescription medicines and animal health. ...See details»
technology - T3 Pharma
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria …See details»
T3 Pharmaceuticals - Craft
T3 Pharmaceuticals has 5 employees at their 1 location and $38.83 m in total funding,. See insights on T3 Pharmaceuticals including office locations, competitors, revenue, financials, …See details»
Boehringer buys cancer immunotherapy firm T3 for $507m
6 days ago Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.See details»
T3 Pharma acquired by Boehringer Ingelheim for up to 450M
Nov 22, 2023 Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharma – one of the first companies that BaseLaunch has financed – for an amount of up to …See details»
Boehringer Ingelheim acquires T3 Pharma for $509m
Nov 23, 2023 T3 Pharma will remain headquartered near Basel, Switzerland, with operations being kept in the region. As part of the acquisition, Boehringer Ingelheim will add T3 Pharma’s …See details»